PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/69184

Please be advised that this information was generated on 2019-02-27 and may be subject to change.
these issues from clinicians, patients, and the medical-device industry.

Daniel G. Schultz, M.D.
Food and Drug Administration
Rockville, MD 20850
exsec@fda.hhs.gov


THE AUTHOR REPLIES: Because of their inherent complexity and widespread distribution, medical devices will occasionally malfunction, fail, or cause unexpected adverse events. It is challenging to predict the long-term performance of implanted devices on the basis of bench testing or premarketing clinical trials of short duration. Thus, for selected life-sustaining products, postmarketing studies of sufficient size and duration must be required of manufacturers. Unfortunately, when questions first arose about the performance of the Medtronic Sprint Fidelis ICD lead, the available postmarketing data were insufficient to allow an accurate evaluation of the device’s performance. Over the ensuing months, tens of thousands of additional patients underwent implantation of the lead, only to be notified of its recall a short time later.

There is no “deeper” problem than the unnecessary exposure of patients to an underperforming permanently implanted medical device. Schultz outlines several important questions that must be answered in order to strengthen the device-approval and postmarketing-monitoring processes. In addition, technological advances such as remote, wireless device monitoring will, in some cases, facilitate collection of the needed performance data. More critical, however, is the need for a philosophical shift — from a medical-device industry that primarily reacts to performance failures to one that better anticipates them.

William H. Maisel, M.D., M.P.H.
Beth Israel Deaconess Medical Center
Boston, MA 02215
wmaisel@bidmc.harvard.edu

Mechanical Ventilation and Disuse Atrophy of the Diaphragm

TO THE EDITOR: In their article, Levine et al. (March 27 issue) conclude that atrophy of the human diaphragm occurs with mechanical ventilation; this finding is consistent with our observation of atrophy of the diaphragm in a patient with a high spinal cord injury after 8 months of mechanical ventilation necessitated by the failure of one diaphragmatic pacemaker. In this patient, atrophy of the diaphragm was prevented in the hemidiaphragm connected to the functioning pacemaker by stimulating the pacemaker for only 30 minutes per day. Levine et al. speculate as to whether there are functional implications due to atrophy and whether strategies can be used to prevent atrophy. Our study addresses both of these questions. First, we found that atrophy was associated with profound reductions in tidal volume. Second, we found that stimulation of the phrenic nerve of the diaphragm for 30 minutes per day was sufficient to prevent atrophy. From our observations and those of Levine et al., one major question arises: Is the diaphragmatic activation associated with the forms of ventilation commonly used in the intensive care unit sufficient to prevent disuse atrophy?

Dennis McCool, M.D.
Brown University
Providence, RI 02860
f_mccool@brown.edu

Najib Ayas, M.D.
University of British Columbia
Vancouver, BC V6T 1Z4, Canada

Robert Brown, M.D.
Massachusetts General Hospital
Boston, MA 02114


TO THE EDITOR: Levine and colleagues confirm that in the absence of respiratory effort, mechanical ventilation for as little as 1 day causes profound atrophy of the diaphragm in adult humans, as it does in animals. Two decades ago, Knisely...
and others reported dramatic evidence of ventilation-induced atrophy in infants. They compared autopsy material obtained from 13 infants who died after mechanical ventilation for at least 12 days with that obtained from 26 infants who died after ventilation for 7 or days or less. Infants who were ventilated for a longer time had smaller diaphragm myofibers with histologic features of disuse atrophy, whereas strap and tongue muscles appeared to be normal. To control for the nutritional and catabolic effects of illness, they assessed ratios of the cross-sectional areas of myofibers in the diaphragm to those of the strap or tongue muscle; both ratios were much lower among the subjects who were ventilated for a longer time. The rapidity of disuse atrophy reported by Levine and colleagues militates against prolonged total rest of the diaphragm in many adults as well as infants who are at risk for hypercapnic respiratory failure.

Stephen H. Loring, M.D.
Beth Israel Deaconess Medical Center
Boston, MA 02215
sloring@bidmc.harvard.edu


TO THE EDITOR: Levine et al. report atrophy of the diaphragm muscle due to disuse in mechanically ventilated patients. Some issues have not been addressed appropriately. Brain death is associated with alteration in the mitochondrial function of skeletal muscle. This alteration may induce oxidative stress and subsequent protease activation resulting in myosin loss. Information about cellular energy failure in brain-dead patients may be provided by the ratio of lactate to pyruvate in plasma.

Atrophy was investigated solely by measuring cross-sectional area. Levine and colleagues propose that a reduction in the cross-sectional area would predict an approximately 55% decrease in transdiaphragmatic pressure. However, a reduction in the cross-sectional area is not necessarily accompanied by reduced force generation. Conversely, we found that in patients with chronic obstructive pulmonary disease, the cross-sectional area of the diaphragm was not different from that of controls, but single-fiber force generation was significantly reduced (by approximately 27%), which could be explained by a loss of myosin of approximately 29%. Thus, a prediction of reduction in force should not be based on cross-sectional area, but rather on myosin content.

Leo M.A. Heunks, M.D., Ph.D.
Richard P.N. Dekhuijzen, M.D., Ph.D.
University Medical Center Nijmegen
6500 HB Nijmegen, the Netherlands
l.heunks@ic.umcn.nl


TO THE EDITOR: Levine and colleagues report on the effects of controlled mechanical ventilation on atrophy of the diaphragm. Although they cite other potential contributors to atrophy of the diaphragm (e.g., systemic inflammatory response syndrome and sepsis), they do not mention critical-illness polyneuropathy and myopathy and some of its risk factors, which also may lead to muscle atrophy and dysfunction of the diaphragm in these patients. Critical-illness polyneuropathy and myopathy is common, with a prevalence ranging from 30 to 90%, and it may develop quickly after the onset of critical illness. Glycemic control may be an important strategy to mitigate critical-illness polyneuropathy and myopathy. In this study, the blood glucose level was significantly higher in case patients versus controls (164 vs. 92 mg per deciliter, P<0.001), and only 4 of 14 patients received insulin infusions. We posit a potential “two-hit” hypothesis, with an interaction between muscle inactivity and the early development of subclinical critical-illness polyneuropathy and myopathy, contributing to rapid muscle atrophy in critically ill patients. This hypothesis requires investigation in future studies. Increasing awareness of critical-illness polyneuropathy and myopathy and further research on reversible risk factors and potential therapies are needed to ameliorate weakness and diaphragmatic dysfunction in critically ill patients.

Eddy Fan, M.D.
Dale M. Needham, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD 21205
eddy.fan@jhmi.edu
We also agree with Loring’s comments about the article by Knisely et al. Since their infant study subjects were not brain-dead, their observations provide support for our concept that brain death per se was not playing a major role in eliciting the myofiber atrophy observed in the diaphragms of our case subjects.

With regard to the comments by Heunks and Dekhuijzen, because of the lack of clinical and histologic data in the article by Sztark et al., the mitochondrial dysfunction that they observed in the long peroneal muscle of their brain-dead organ-donor subjects may represent early changes associated with disuse in this limb muscle. Second, myosin concentration was not measured in our diaphragm-biopsy specimens. Therefore, in our predictions of the maximum force-generating capacity of the diaphragm, we used measured cross-sectional areas, fiber-type proportions, and assumed normal specific force for the diaphragm-biopsy specimens from both case subjects and controls. If the increased proteolysis observed in the diaphragms of the case subjects was accompanied by a decrease in myosin concentration, as compared with the diaphragms of the controls, the diaphragms of the case subjects would have shown a greater decrease in force-generating capacity than that estimated in our article (i.e., a decrease in transdiaphragmatic pressure of >55%).

We agree with Fan and Needham that our case subjects had hyperglycemia, which is a risk factor for both critical-illness polyneuropathy and myopathy. Therefore, these conditions should be considered as possible causes of atrophy of diaphragm myofibers. The absence of necrosis and hypercellularity in the diaphragm-biopsy specimens of our case subjects rules out the myopathy associated with the critical-illness polyneuropathy and myopathy syndrome. Since we did not obtain sections of phrenic nerve, we cannot rule out a neural contribution to the atrophy of diaphragm fibers observed in our case subjects.

Regarding the concerns of Leo and Spaggiari, we do not believe that either trauma or malnutrition played a role in eliciting the atrophy of diaphragm fibers in the case subjects because we excluded subjects with thoracoabdominal trauma from our case cohort and because these patients showed no signs of malnutrition; indeed, our data indicate that case and control subjects did not differ with respect to body-mass index.
Cholesterol Gene Polymorphisms and Cardiovascular Events

TO THE EDITOR: Kathiresan and coworkers (March 20 issue) find that a genotype score of nine, which was crafted from a combination of four single-nucleotide polymorphisms (SNPs) affecting high-density lipoprotein (HDL) cholesterol and five SNPs influencing low-density lipoprotein (LDL) cholesterol, is an independent risk factor for incident cardiovascular disease. Similarly, Willer et al. recently showed that 11 SNPs associated with elevated LDL levels (most of which overlap with the genes included in the article by Kathiresan et al.) increase the risk of coronary artery disease. In contrast, the HDL-modulating SNPs reported by Willer et al. were not associated with the risk of coronary artery disease, although the HDL genes (cholesterol ester transfer protein [CETP], hepatic lipase [LIPC], lipoprotein lipase [LPL], and ATP-binding cassette subfamily A member 1 [ABCA1]) were similar to those in the article by Kathiresan et al. By presenting a combined genotype score comprising distinct risk factors (i.e., HDL cholesterol and LDL cholesterol), Kathiresan et al. imply a predictive value of all of these SNPs; this is in clear contrast to the findings of Willer et al. Therefore, it would have been much more informative if the genotype scores for LDL and HDL genes had been reported separately, thereby allowing closer comparison with related studies.

Menno Vergeer, M.D.
Karim El-Harchaoui, M.D.
Erik S.G. Stroes, M.D.
Academic Medical Center
1105 AZ Amsterdam, the Netherlands


TO THE EDITOR: Genotype scores for risk prediction are becoming increasingly popular; for instance, the use of these scores has recently been proposed to predict cardiovascular disease and prostate cancer. The concept relies on two major assumptions. First, polymorphisms act independently and additively on the risk of disease. Second, their effects are approximately interchangeable. The first assumption may be true, especially with regard to polymorphisms belonging to different biologic systems, but in practice it cannot be verified because current studies are underpowered to do so. The second assumption is very questionable. For example, in the study reported by Kathiresan et al., the difference in the LDL cholesterol level between homozygote genotypes was 72 mg per deciliter for the proprotein convertase subtilisin/kexin type 9 (PCSK9) polymorphism and 3 mg per deciliter for the LDL receptor (LDLR) polymorphism. Similarly, in terms of risk, the score assumed that it is equivalent to carry HDL-lowering or LDL-increasing alleles, despite the fact that a score based only on HDL-related genotypes led to a hazard ratio of 1.22, as compared with 1.11 for a score based on LDL-related genotypes. Paradoxically, such scores take us away from the goal of individualized medicine.